Radient Pharmaceuticals Corp. (RPC) to Exhibit Cancer Test at Annual Leading Oncology Meeting in Chicago

QualityStocks would like to highlight Radient Pharmaceuticals Corporation (AMEX: RPC) is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and therapeutic products, such as diagnostic tests that assist physicians in answering important clinical questions related to early disease detection, including its Onko-Sure® In Vitro Diagnostic (IVD) cancer test.

In the company’s news yesterday,

Radient Pharmaceuticals announced it will exhibit its Onko-Sure® cancer test at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-6, 2011.

The Onko-Sure cancer test kit has been cleared by the FDA for colo-rectal cancer treatment and recurrence monitoring. The company will have the opportunity to discuss Onko-Sure and relative information with the thousands of oncology professionals at the meeting in Chicago.

“Participating in ASCO 2011 is another step forward in increasing awareness of Onko-Sure through outreach to key opinion leaders on a national and international level. Providing published clinical study results and our product’s strengths at scientific conferences is a key component of building adoption rates for Onko-Sure® globally,” Radient’s director of oncology, Dr. Motamed-Khorasani, stated in the press release.

Dr. Motamed-Khorasani will join Radient’s director of international sales and marketing Christopher Gee as participants and exhibitors at the meeting.

“As a cancer test that is in use and cleared to market in numerous territories across the world, we benefit from presenting Onko-Sure® to the international cancer care and research community attending ASCO,” Radient CEO Douglas MacLellan stated. “By having our science and marketing executives available at the event we seek to have meaningful discussions with physicians, medical oncologists, cancer advocacy groups, and healthcare professionals involved in cancer research and testing. It’s also a great opportunity to build relationships with new healthcare and lab partners internationally.”

ASCO is the world’s top professional organization with nearly 30,000 members, which are physicians of all oncology subspecialties.

Last year, ASCO’s annual meeting registered 32,700 attendees, including 26,600 members of the worldwide oncology community, packed with educational and scientific sessions featuring cutting-edge information on the diagnosis and treatment of patients with cancer.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.